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http://dx.doi.org/10.1016/j.stemcr.2016.03.004SUMMARYNotch signaling is an important regulator of stem cell differentiation. All canonical Notch signaling is transmitted through the DNA-
binding proteinCSL, and hyperactivatedNotch signaling is associatedwith tumor development; thus itmay be anticipated that CSL defi-
ciency should reduce tumor growth. In contrast, we report that genetic removal of CSL in breast tumor cells caused accelerated growth of
xenografted tumors. Loss of CSL unleashed a hypoxic response during normoxic conditions, manifested by stabilization of the HIF1a
protein and acquisition of a polyploid giant-cell, cancer stem cell-like, phenotype. At the transcriptome level, loss of CSL upregulated
more than 1,750 genes and less than 3% of those genes were part of the Notch transcriptional signature. Collectively, this suggests
that CSL exerts functions beyond serving as the central node in the Notch signaling cascade and reveals a role for CSL in tumorigenesis
and regulation of the cellular hypoxic response.INTRODUCTION
In most cellular contexts Notch signaling acts as a gate-
keeper to differentiation, promoting maintenance of stem
or progenitor cell fates (Andersson et al., 2011; Guruharsha
et al., 2012). Modulation of Notch signaling is used to con-
trol stem or progenitor cell differentiation in vitro, for
example toward neural, intestinal, or hematopoietic line-
ages (Lowell et al., 2006; Schmitt et al., 2004; Yin et al.,
2014). Deregulated Notch signaling is increasingly linked
to cancer, and Notch receptor mutations are found in, for
example, T cell leukemia, non-small cell lung cancer, and
breast cancer as well as in several types of tumor cell lines
(Mutvei et al., 2015; Robinson et al., 2011; Weng et al.,
2004; Westhoff et al., 2009). Notch signaling is also
frequently hyperactivated in a range of tumors, including
breast cancer (for review see Andersson and Lendahl,
2014).
Notch signaling ensues when transmembrane Notch li-
gands of the Jagged or Delta-like type interact with
Notch receptors on a juxtaposed cell. This results in pro-
teolytic cleavage and liberation of the intracellular
domain of the Notch receptor (Notch ICD), which relo-
cates to the cell nucleus and interacts with the DNA-
binding protein CSL (also known as RBP-Jk or CBF1),
thus making CSL the central node in the signaling
cascade for all four Notch receptors (Notch 1–4) (Ander-
sson et al., 2011). In the ‘‘Notch off’’ state, CSL acts as a
repressor and binds a number of transcriptional co-re-
pressors, such as SHARP/MINT, KDM5A, and KyoT2 (forStem
This is an open access artireview see Borggrefe and Oswald, 2014). In the ‘‘Notch
on’’ state, i.e., upon binding to Notch ICD, CSL sheds
the co-repressors and instead recruits co-activators, such
as p300 and PCAF, converting it to an activator. The
interaction between Notch ICD and CSL is stabilized by
the MAML protein, and the ternary Notch ICD/MAML/
CSL complex induces expression of Notch downstream
genes (Nam et al., 2006; Wilson and Kovall, 2006). It
has traditionally been assumed that CSL serves as a
DNA-bound repressor in the absence of Notch, and in
line with this, CSL can bind to DNA in the absence of
Notch and remains bound to DNA even during mitosis
(Lake et al., 2014). Recent studies, however, provide sup-
port for a more dynamic view whereby CSL is recruited to
the DNA by Notch ICD (Castel et al., 2013; Krejcı´ and
Bray, 2007).
It is an open question whether CSL only transmits the
signal from theNotch receptors or also plays a role in other,
non-Notch-related signaling transductions. Gene-target-
ing experiments show that phenotypes resulting from tar-
geting of Notch ligands or receptors in some situations are
phenocopied by targeting of CSL, for example during somi-
togenesis (Conlon et al., 1995; Oka et al., 1995) or in mem-
ory T cells (Maekawa et al., 2015), which is in line with CSL
functioning exclusively as the central hub in the Notch
signaling cascade (Guruharsha et al., 2012). On the other
hand, there are also an increasing number of proteins,
such as CTCF, EBNA3c, interferon regulatory factor 4, and
RITA (see Collins et al., 2014 and references therein), which
are not part of the Notch signalingmechanism but interactCell Reports j Vol. 6 j 643–651 j May 10, 2016 j ª 2016 The Authors 643
cle under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Figure 1. CSL-Deficient Cells Accelerate
Tumor Growth In Vivo
(A) Schematic representation of CRISPR/
Cas9 targeting of the CSL locus. The triangle
points to the targeted exon. Red letters
represent the guide RNA sequence and
green letters the PAM sequence.
(B) Western blot of CSL and b-actin (loading
control) in control (CSL+/+) and two clones of
CSL-deficient MDA-MB-231 cells (CSL/).
(C) Notch reporter (12x CSL-EGFP) activity
in control and CSL-deficient cells after
transfection of 12xCSL-EGFP, Notch1-ICD
(NICD), and CSL, as indicated. White arrows
indicate cells expressing EGFP.
(D) Average tumor volume at different time
points after xenografting CSL+/+ or CSL/
cells. Eight tumors of four mice per group
were analyzed.
(E) Representative images and H&E stain-
ings of control and CSL-deficient tumors.
(F and G) Analysis of Ki67 (F) and cleaved
Caspase-3 (cCasp3) (G) expression in MDA-
MB-231CSL+/+ and CSL-deficient tumor sec-
tions (enlarged images to the right). At the
bottom of each figure, the number of posi-
tive cells is quantified. Signals of at least
four randomly chosen images from one tu-
mor sample of each kind were counted.
(H) Analysis and quantification of tumor
growth in the chick chorioallantoic mem-
brane (CAM) assay for CSL+/+ and CSL/
cells. At least five different tumors of each
kind were measured.
(I and J) Invasion and migration assays for
CSL+/+ and CSL/ cells. This analysis is based
on at least three independent experiments.
Data are shown as percent of wild-type MDA-
MB-231 DMSO control cells (set to 100%).
Data are presented as mean ± SEM. *p %
0.05; **p % 0.01; ***p % 0.001. ns, not
significant. Scale bars: 100 mm (C), 200 mm
(E lower), 100 mm (F and G), and 75 mm
(F and G inset).with CSL, suggesting that CSL has a broader range of
actions extending beyond only transmitting Notch
signaling.
In this study, we address the question of possible addi-
tional roles for CSL and report the unexpected discovery
that transplanted breast tumor cells in which CSL was
genetically ablated caused rapid tumor growth, a pheno-
type opposite to blocking Notch function at the receptor
level. The phenotype was accompanied by acquisition of
a hypoxic response during normoxia and a polyploid
giant-cell, cancer stem cell-like, morphology.644 Stem Cell Reports j Vol. 6 j 643–651 j May 10, 2016RESULTS
Loss of CSL Promotes Tumor Growth In Vivo
To explore the role of CSL in a breast tumor context, we tar-
geted both CSL alleles by CRISPR/Cas9 genome editing in
MDA-MB-231 cells (Figure 1A), a breast tumor cell line
with active Notch signaling and which promotes tumor
growth when transplanted in vivo (Holliday and Speirs,
2011; Jin et al., 2013). In the two independent MDA-MB-
231CSL/ clones selected for further analysis, there was
as expected no detectable CSL protein (Figure 1B), and
the activity of a Notch reporter construct (12x CSL-EGFP)
(Hansson et al., 2006) was abrogated (Figure 1C). Reintro-
duction of CSL into the MDA-MB-231CSL/ cells restored
Notch reporter activity (Figure 1C) as well as expression
of established Notch downstream genes (Figure S1).
Transplantation of the MDA-MB-231CSL/ cells into the
mammary fat pad in mice resulted in accelerated tumor
growth compared with control MDA-MB-231CSL+/+ cells.
The difference was already noticeable after 3 weeks, and
after 5 weeks the tumor volume from the MDA-MB-
231CSL/ cells was 2.8 times larger than in the control cell
line (Figures 1D and 1E). Proliferation was increased and
apoptosis decreased in the MDA-MB-231CSL/ tumors as
determined by Ki67 (Figure 1F) and cleaved Caspase-3 (Fig-
ure1G) staining, respectively. Toassess tumorgrowthpoten-
tial inanalternativemanner,weculturedbothCSL-deficient
clones on the chorioallantoicmembrane in eggs, and tumor
growth was robustly enhanced for both clones (Figure 1H).
In keeping with the tumor data, both CSL/ clones dis-
played elevated penetration in a Matrigel invasion assay
(Figure 1I). In a transwell migration assay, clone #1 showed
enhanced migration whereas migration was not signifi-
cantly changed in clone #2 (Figure 1J). Treatment with
the g-secretase inhibitor DAPT, which blocks receptor
cleavage and thus Notch1 ICD generation, inhibited cell
migration and reduced the invasion of CSL+/+ but not of
CSL-deficient cells (Figures 1I and 1J). In conclusion, these
data show that removal of CSL enhances tumor growth
in vivo and invasiveness in vitro, and exerts an effect
distinct from blockade at the Notch receptor level.
Loss of CSL Unleashes a Hypoxic Response under
Normoxic Conditions
Hypoxia is an important regulator of tumor growth (Jain,
2014), and hypoxia andNotch signaling intersect in several
ways (Gustafsson et al., 2005; Sahlgren et al., 2008; Zheng
et al., 2008). This promptedus to assesswhether thehypoxic
responsewas altered inCSL/ cells.Undernormoxic condi-
tions the steady-state level of the transcriptional regulator
HIF1a is very low, andHIF1aonly becomes stabilizedduring
hypoxia. The two MDA-MB-231CSL/ clones analyzed
above as well as two additional clones showed elevated
HIF1a protein levels during normoxia compared with the
low levels seen in control cells under normoxia (Figure 2A;
see Figure S2A for quantification). Reintroduction of CSL
into the MDA-MB-231CSL/ cells abrogated the increase
inHIF1aprotein levels (Figure S2B). The elevatedHIF1apro-
tein levels were a result of post-transcriptional events, as the
mRNA levels were similar in CSL+/+ and CSL/ cells (Fig-
ure 2B). Activation of hypoxia downstream genes was also
observed: in clone #1, VEGF-A gene expression was upregu-
lated, whereas the STC2 and KLF8 genes showed elevated
expression in clone #2 (Figure 2C). In keepingwith hypoxiaas a potent regulator of tumor vascularization (Rapisarda
and Melillo, 2012), vascularization was enhanced around
the tumors fromCSL/ cells (datanot shown), andcollagen
IV and CD31 immunostaining (as endothelial markers) in
the tumors was elevated (Figure 2D).
Interaction between endogenous Notch1 ICD and HIF1a
was observed in the MDA-MB-231CSL/ cells (Figure S2C),
and blocking Notch ICD generation by DAPT reduced the
amount of HIF1a in control cells and to a lesser extent in
the CSL-deficient clones under normoxic conditions (Fig-
ure 2E; see Figure S2D for quantification). Under hypoxic
conditions HIF1a levels were not altered in control but
reduced in CSL-deficient cells following DAPT treatment
(Figure 2E; see Figure S2D for quantification). HIF1a can
be stabilized in normoxia and is influenced by nitric oxide
and redox potential (Palmer et al., 2000), and we therefore
investigated whether the normoxically elevated level of
HIF1a in the CSL/ cells was susceptible to the reducing
agent DTT. Treatment by DTT resulted in a decrease in
HIF1a in CSL/ cells, as well as in the low level of HIF1a
in control cells, during normoxia, whereas HIF1a was
largely unresponsive in the hypoxic CSL-deficient cells
(Figure 2F; see Figure S2E for quantification). In conclusion,
these data show that HIF1a levels are regulated by CSL.
CSL-Deficient Cells Acquire a Polyploid Giant-Cell
Phenotype and a Mitosis Defect
Both MDA-MB-231CSL/ clones were morphologically
heterogeneous and presented subcellular populations
with a cellular morphology that was distinct from the con-
trol cells when cultured in vitro. The phenotype was char-
acterized by cells having a large volume and containing
either a giant nucleus or a fragmented polyploid nucleus,
and the giant cells were frequently surrounded by small-
sized cells (Figures 3A and 3B). To determine the origin of
the giant-cell phenotype, we monitored control and
CSL/ cells by time-lapse live-cell microscopy (Figure 3C).
Single-cell analysis ofmitotic progression in both giant and
normal-sized cells revealed that a large proportion of
CSL/ cells presented aberrant mitosis, with cells dividing
into multiple daughter cells or by exiting mitosis without
dividing into two daughter cells (Figures 3B and 3C, lower
panel; videos in Figure S3A). TheCSL/ cells (clone #2) dis-
played a decreased proliferation rate in vitro, and reintro-
duction of CSL restored the proliferation rate observed in
control cells (Figures S3B and S3C). In sum, these observa-
tions show that loss of CSL affects cell morphology and
leads to a mitotic defect.
ANotch-Independent Transcriptional Signature in the
CSL-Deficient Cells
We next assessed the transcriptional consequences of CSL
deficiency, i.e., whether loss of CSL resulted in onlyStem Cell Reports j Vol. 6 j 643–651 j May 10, 2016 645
Figure 2. Unleashing Hypoxic Activation
and Angiogenic Activity by CSL-Deficient
Cells
(A) Western blot of HIF1a, CSL, and b-actin
(loading control) in control and CSL-defi-
cient MDA-MB-231 cells under normoxic
(left) and hypoxic (1% O2; right) condi-
tions.
(B and C) qPCR analysis of HIF1a (B) and
VEGF-A (clone #1) and STC2 and KLF8 (clone
#2) (C) mRNA expression in control and
CSL/ cells. mRNA expression level anal-
ysis is based on three separate experiments.
(D) Representative images of collagen IV
(COLIV) and CD31 expression in control and
CSL-deficient xenografts. Quantification of
the CD31 staining is shown to the right.
Signal quantification is based on at least
three randomly chosen images from one
tumor sample of each kind. Scale bar,
100 mm.
(E and F) Western blot of HIF1a and b-actin
in control and CSL-deficient MDA-MB-231
cells under normoxic or hypoxic conditions.
Cells were cultured in the presence or
absence of DTT (E) or DMSO/DAPT (F), as
indicated.
Data are presented as mean ± SD. *p %
0.05; **p % 0.01; ***p % 0.001. ns, not
significant.derepression of a Notch transcriptional signature or
affected a larger non-Notch-dependent gene set. TheNotch
transcriptional signature was identified as genes upregu-
lated by ligand activation and where the ligand-induced
upregulation was abrogated by blocking Notch receptor
cleavage using DAPT. RNA-seq analysis revealed 139 genes
that were ligand-activated and sensitive to DAPT,
and which we denote the Notch signature (Figure 4A).
This gene set contained a number of well-established
Notch downstream targets, such asHES1,HES4, andNRARP646 Stem Cell Reports j Vol. 6 j 643–651 j May 10, 2016(Figure 4A).Wenext compared the transcriptomes ofMDA-
MB-231CSL/ and control cells, and 1,768 geneswere upre-
gulated in theCSL-deficient cells (Figure 4A). GSEA analysis
revealed that this gene set was enriched for genes
associated with KRAS and TNFa signaling or involved in
angiogenesis, G2M checkpoint or apical junctions, and
epithelial-to-mesenchymal transition. In line with this,
MMP1 was also significantly upregulated in CSL/ cells
(Figure S4A). A comparison between the 1,768 genes and
the 139 genes in the Notch signature revealed that only
Figure 3. Acquisition of a Polyploid Gi-
ant-Cell Phenotype in the CSL-Deficient
Cells
(A) Brightfield images of CSL+/+ and CSL/
cells (upper panel) and high-magnification
view of CSL+/+ and CSL/ cells stained with
DAPI and b-tubulin (lower panel). Giant
cells are marked with arrows and polyploid
cells are marked with arrowheads.
(B) Proportion of cells without mitotic exit
division and cells generating several
daughter cells among CSL+/+ and CSL/
cells. At least 50 cells of each clone were
analyzed.
(C) Time-lapse images of control and CSL-
deficient cells. The white arrowheads
denote cells analyzed by time-lapse imag-
ing.
Scale bars: 100 mm (A upper), 50 mm
(A lower), and 50 mm (C).47 genes were common to both categories (Figure 4A). The
limited overlapwas corroborated by a principal component
analysis (PCA) showing that CSL/ cells clustered quite
distinctly from control cells, and that ligand activation
and DAPT treatment had quite limited effects on the tran-
scriptomes in the CSL/ cells, whereas the effect was more
profound in the control cells (Figure 4B).
To assess how CSL deficiency affected the transition
from in vitro culture to the in vivo tumor situation, we
compared the transcriptome from in vitro culturing with
that from tumors at early and late stages after xenograft-
ing, using the S3 technology to bioinformatically sort
out the tumor (human) from the stromal (mouse) tran-
scripts (Chivukula et al., 2015). PCA revealed that the
in vitro transcriptomes from MDA-MB-231CSL/ and
control cells were quite distinct and that the differences
were maintained in the tumor situation (Figure 4C). Inter-
estingly, when tumor cells were excised and returned to
in vitro culture the transcriptomes largely reverted back
to more closely resemble the respective in vitro transcrip-
tomal profile observed prior to transplantation (Figure 4C).
Finally, single-cell transcriptome analysis showed that
MDA-MB-231CSL/-derived tumors were more homoge-neous than MDA-MB-231CSL+/+-derived tumors, and
cellular homogeneity further increased at the later tumor
stage (Figure 4D). In sum, these data suggest that CSL
transcriptionally controls a number of genes that are
not part of a core Notch signature.DISCUSSION
CSL serves as the central node in canonical Notch signaling
by transmitting signaling from all Notch receptors upon
ligand activation. In this work, we report that genetic abla-
tion of CSL in breast tumor cells leads to enhanced tumor
growth after transplantation into mammary fat pads in
mice, an unexpected finding given that blocking of Notch
at the receptor level reduces and activation of Notch pro-
motes tumor growth (Bolo´s et al., 2013; Suman et al.,
2013).
The genome-wide transcriptome data support the view
that CSL does not merely mediate Notch signaling, as the
set of genes upregulated by CSL ablation was consider-
ably larger than the Notch signature in the MDA-MB-
231 cells. This conclusion differs from a recent report,Stem Cell Reports j Vol. 6 j 643–651 j May 10, 2016 647
Figure 4. A Notch-Independent Tran-
scriptional Signature in the CSL-Deficient
Cells
(A) (Left) Heatmap of the 139 genes that
constitute the Notch signature, i.e., genes
which are upregulated by ligand (Jag1)
stimulation and where gene expression is
abrogated by DAPT. (Right) Heatmap of the
1,768 genes that were upregulated in CSL-
deficient cells compared with control cells.
Lower panel: Venn diagram showing the
comparison of the Notch signature genes
and genes upregulated in CSL-deficient
cells.
(B) PCA of genome-wide transcriptome
analysis for CSL+/+ and CSL/ cells during
ligand activation (Jag1) and inhibition by
DAPT (n = 2 for each treatment).
(C) PCA of genome-wide transcriptome
analysis for CSL+/+ and CSL/ cells during
in vitro culturing prior to tumor xenograft-
ing, the xenograft tumors, and when re-
turned to in vitro culture after xenografting,
as indicated.
(D) Correlation plot of single-cell RNA-seq
analysis from CSL+/+ and CSL/ cells in
tumors from early (3 weeks) and late
(5 weeks) stages.which used small hairpin RNA to knock down CSL
expression in MDA-MB-231 cells (Kulic et al., 2014).
While Kulic et al. (2014), like us, showed that reduced
CSL expression in MDA-MB-231 cells promotes tumor
growth, they argue that the observed phenotype was
linked to derepression of Notch-activated genes. This
notion, however, was based on gene-expression analysis
of a set of only 170 genes that were on theoretical
grounds considered to be Notch responsive (Kulic et al.,
2014). Only five of the 170 genes, however, were among
the 1,768 genes upregulated in the CSL/ cells and only
two genes were common to the 139 genes in our Notch648 Stem Cell Reports j Vol. 6 j 643–651 j May 10, 2016signature (Figures S4B and S4C). The notion that CSL
has Notch-independent functions is in line with the
fact that CSL interacts with a number of proteins that
are not linked to Notch signaling, such as CTCF, EBNA3c,
interferon regulatory factor 4, and RITA (Collins et al.,
2014). One hypothesis to explain the large Notch-inde-
pendent gene set posits that CSL binds to a larger number
of genomic sites, only a subset of which can bind Notch
ICD, and loss of CSL would thus lead to derepression also
of Notch-independent genes. Recent data, however, sup-
port a view whereby CSL is dynamically recruited by
Notch ICD and not statically bound as a repressor (Castel
et al., 2013; Krejcı´ and Bray, 2007). An alternative hy-
pothesis is that CSL may not directly repress all genes
whose expression is altered, but rather control expression
of a smaller set of chromatin modifiers or transcriptional
regulators, which in turn reset the chromatin landscape
and/or alter gene expression on a broader scale. In sup-
port of this view, we noted that expression of a number
of such factors, such as Serpin, was upregulated in the
CSL-deficient cells. That loss of CSL enhances tumor
development is further underlined by a recent study re-
porting that combined silencing of CSL and p53 in can-
cer-associated fibroblasts leads to stromal and cancer
cell expansion (Procopio et al., 2015).
An unexpected consequence of removing CSL was the
unlocking of a hypoxic response during normoxia, mani-
fested by a post-transcriptional elevation of HIF1a protein
levels and the upregulation of hypoxia-regulated genes
such as VEGF-A, STC2, and KLF8. This is in line with pre-
vious reports on normoxic HIF1a protein stabilization
(Palmer et al., 2000; Ranasinghe et al., 2015; for review
see Kuschel et al., 2012), and adds to the emerging view
of a multifaceted interplay between Notch and the
cellular hypoxic response (Andersson and Lendahl,
2014; Lendahl et al., 2009). Notch1 ICD interacted with
HIF1a, and it is noteworthy that blocking Notch ICD gen-
eration reduced the amount of HIF1a, raising the
intriguing possibility that Notch ICD in some way plays
a role in the observed HIF1a stabilization. Furthermore,
the HIF1a protein levels in the CSL-deficient cells were
reduced by DTT treatment, suggesting a role for redox po-
tential, possibly linked to nitrosylation of HIF1a (Palmer
et al., 2000) or destabilization of the ODD domain. The
unleashing of a hypoxic response during normoxia may
also be linked to the acquisition of aberrant cell
morphology, a phenotype strongly reminiscent of the
recently described polyploid giant cancer cell (PGCC)
phenotype (Zhang et al., 2014). Interestingly, PGCC cells,
which are endowed with cancer stem cell-like properties,
were recently identified in a number of tumor contexts
in response to hypoxia or chemical induction of the hyp-
oxic response by CoCl2 (Zhang et al., 2014), suggesting
that loss of CSL may lead to a PGCC-like state via upregu-
lation of HIF1a. As PGCC cells are endowed with reduced
proliferative rate in vitro combined with accelerated tu-
mor growth capacity (Zhang et al., 2014), the induction
of HIF1a protein levels in the CSL-deficient cells may un-
derlie their enhanced growth rates, invasive capacity, and
accelerated tumor growth.
In conclusion, the data in this report provide evidence
for a role for CSL in controlling the cellular hypoxic
response and cell cycle/cytokinesis as well as tumor
growth. The data also indicate that CSL acts beyond only
mediating Notch signaling.EXPERIMENTAL PROCEDURES
CRISPR/Cas9 Genome Editing
Designed guide RNA sequence targeting CSL (50-AAACATTGTA
TATATCTGAC-30) was cloned and ligated to the guide RNA
vector (Addgene). Cells were co-transfected with the guide RNA
vector and the Cas9 expression vector. Single-cell colonies were
isolated and subjected to Western blot and DNA-sequencing
analysis.
Mammary Fat Pad Xenograft
All animal procedures were approved by the Stockholm’s
North Ethical Committee for Animal Research (permit No
N151/14). 1.5 3 106 MDA-MB-231 control or CSL-deficient cells
in culture media were orthotopically injected into the left and
right fourth inguinalmammary fat pads of 4- to 6-week-old female
immunodeficient NOD/SCID mice. Tumor growth and size was
measured twice per week using calipers. Tumor volume was calcu-
lated according to the formulaL3W2.Micewere euthanized at the
third and fifth week after transplantation.
Statistical Analysis
All statistical analyses were calculated by GraphPad Prism (ver. 6).
For further details see Supplemental Information.
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